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BACKGROUND
Eculizumab, a humanized monoclonal antibody against complement protein C5 
that inhibits terminal complement activation, has been shown to prevent compli-
cations of paroxysmal nocturnal hemoglobinuria (PNH) and improve quality of life 
and overall survival, but data on the use of eculizumab in women during preg-
nancy are scarce.
METHODS
We designed a questionnaire to solicit data on pregnancies in women with PNH 
and sent it to the members of the International PNH Interest Group and to the 
physicians participating in the International PNH Registry. We assessed the safety 
and efficacy of eculizumab in pregnant patients with PNH by examining the birth 
and developmental records of the children born and adverse events in the mothers.
RESULTS
Of the 94 questionnaires that were sent out, 75 were returned, representing a re-
sponse rate of 80%. Data on 75 pregnancies in 61 women with PNH were evalu-
ated. There were no maternal deaths and three fetal deaths (4%). Six miscarriages 
(8%) occurred during the first trimester. Requirements for transfusion of red cells 
increased during pregnancy, from a mean of 0.14 units per month in the 6 months 
before pregnancy to 0.92 units per month during pregnancy. Platelet transfusions 
were given in 16 pregnancies. In 54% of pregnancies that progressed past the first 
trimester, the dose or the frequency of use of eculizumab had to be increased. 
Low-molecular-weight heparin was used in 88% of the pregnancies. Ten hemor-
rhagic events and 2 thrombotic events were documented; both thrombotic events 
occurred during the postpartum period. A total of 22 births (29%) were prema-
ture. Twenty cord-blood samples were examined for the presence of eculizumab; 
the drug was detected in 7 of the samples. A total of 25 babies were breast-fed, 
and in 10 of these cases, breast milk was examined for the presence of eculi-
zumab; the drug was not detected in any of the 10 breast-milk samples.
CONCLUSIONS
Eculizumab provided benefit for women with PNH during pregnancy, as evidenced 
by a high rate of fetal survival and a low rate of maternal complications. (Clinical-
Trials.gov number, NCT01374360.)
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Paroxysmal nocturnal hemoglobin-uria (PNH) is a rare, acquired stem-cell disorder that is characterized by chronic 
hemolysis, bone marrow failure, and venous 
thromboembolism.1-3 Manifestations of the disease 
are related primarily to complement-mediated 
hemolysis. Patients with PNH present with a wide 
range of clinical symptoms, and if they do not 
receive specific treatment for the disorder, they 
can have a chronic, progressive illness and an 
increasing risk of death, primarily from thrombo-
sis, over time (the median survival from the time 
of diagnosis ranges from 10 to 32 years).1-3
Historically, the management of PNH during 
pregnancy has been challenging, and pregnancy 
has been discouraged in patients with PNH.4-6 
Intravascular hemolysis and anemia are frequent-
ly more severe during pregnancy, with greater 
transfusion requirements, than in the nonpreg-
nant state.7-9 Morbidity and mortality are higher 
among pregnant women with PNH than among 
nonpregnant women with PNH, and the risks 
continue to be high during the postpartum pe-
riod. Fetal morbidity and mortality are higher 
among pregnant women with PNH than among 
pregnant women without PNH.6,8,9 Maternal mor-
tality has been reported to be between 8% and 
20.8%, with thromboembolism as the primary 
cause of death; the majority of thrombotic 
events occur during the postpartum period.5,6,8,10 
Fetal mortality has been reported to be between 
4% and 9%.6,8,10 This high fetal mortality associ-
ated with pregnancies in patients with PNH is 
related to premature births, with only half the 
pregnancies progressing to term in one study.8
Terminal complement formation increases dur-
ing pregnancy, and in cases of preeclampsia, 
terminal complement activation is even more 
pronounced.11,12 Eculizumab is a humanized 
monoclonal antibody that binds to the comple-
ment protein C5 and blocks terminal comple-
ment activation.13 Clinical trials involving patients 
with PNH have shown that eculizumab prevents 
disease complications and improves quality of 
life and overall survival.14-17 Because young wom-
en with PNH who have received treatment with 
eculizumab have a reduction in their symptoms, 
they are more likely to consider pregnancy.
Currently, there are few data on the use of 
eculizumab during pregnancy, with only four 
cases reported18-21 and one small case series in-
volving seven patients.22 In addition, one report 
on two pregnancies specifically examined wheth-
er eculizumab crosses the placenta.23 Here we 
present data gleaned from the international 
PNH community on 75 pregnancies in 61 women 
that were documented after eculizumab became 
available for use in 2007.
Me thods
Study Design and Oversight
We designed a questionnaire to solicit data on 
pregnancies in women with PNH (see the Sup-
plementary Appendix, available with the full text 
of this article at NEJM.org). The work was per-
formed in association with the International 
PNH Registry. The questionnaire was sent to the 
members of the International PNH Interest Group 
and to physicians participating in the Interna-
tional PNH Registry.24
The data were collected by the authors and 
the collaborators listed in the Supplementary 
Appendix. The first, second, third, and last au-
thors interpreted the data and wrote the manu-
script. The registry sponsor had no role in the 
study. Written informed consent by the patients 
was obtained for the International PNH Registry 
(www . pnhregistry . com) and the Italian PNH reg-
istry (Registro EPN–Emoglobinuria Parossistica 
Notturna; www . iss . it/ cnmr/ index . php?lang=1&id= 
2325&tipo=14). The collection of the data for the 
registries was not restricted for a specific pur-
pose; therefore, no additional approval for anal-
ysis was necessary. Approval for the registries 
was granted by institutional review boards or 
the equivalent of the centers at which the par-
ticipating physicians work. The study was per-
formed in accordance with the principles of the 
Declaration of Helsinki.
Diagnosis and Treatment of PNH
A diagnosis of PNH was established by means of 
flow cytometry. Information was collected on the 
dates of diagnosis, history of thrombosis and 
aplasia, and outcomes of pregnancies before 
eculizumab was available for use. Transfusion 
history and medication use were evaluated.
Maternal and Fetal Complications  
and Childhood Development
Obstetrical data included the number of pregnan-
cies, miscarriages, and deliveries, as well as the 
term and mode of delivery. Premature delivery 
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was defined as delivery before 37 weeks of gesta-
tion, which was determined by means of ultra-
sonography. Newborn vital status and birth 
weight were recorded. The postpartum period 
was defined as the period between delivery and 
6 months after delivery, because the delayed 
postpartum phase can last for 6 months. Mater-
nal and fetal complications during pregnancy, at 
delivery, and during the postpartum period were 
recorded.
Eculizumab Therapy
Therapy with eculizumab was commenced at the 
discretion of the treating physician. Eculizumab 
was administered as a weekly intravenous infu-
sion at a dose of 600 mg for 4 weeks, followed 
by 900 mg every 14 days. The dose or the fre-
quency of use of eculizumab was increased when 
there was evidence of breakthrough intravascu-
lar hemolysis. We obtained maternal and cord-
blood samples in the case of some pregnancies, 
as well as breast-milk samples from some mothers, 
to evaluate whether levels of eculizumab were 
detectable (assay lower limit of detection, 5 μg 
per milliliter). The decision to initiate anticoagu-
lation therapy in a patient was made at the dis-
cretion of the treating physician.
R esult s
Characteristics of the Patients
We identified 75 pregnancies in 61 women 
with PNH, who were followed up at 31 centers 
in 9 countries during the period from June 2006 
through November 2014. Three patients had 
3 pregnancies each, and 8 patients had 2 preg-
nancies each. Three pregnancies involved twins, 
and among these pregnancies a fetal loss of 
1 twin occurred in utero. One patient discontin-
ued eculizumab therapy at 12 weeks of gestation. 
Overall, there were 69 live births, 6 spontaneous 
abortions during the first trimester, and 3 still-
births.
The characteristics of the patients and the 
history of pregnancies in these patients before 
they began to receive eculizumab are shown in 
Table 1. The median age of the patients at the 
time of diagnosis of PNH was 23 years (range, 
13 to 37), and the median age at the start of 
their pregnancies was 29 years (range, 18 to 40). 
In most cases, pregnancy occurred in patients 
who had previously received a diagnosis of PNH; 
in 46 of the 75 pregnancies (61%) included in this 
analysis, the patients had been using eculizumab 
before conception. The median time from the 
diagnosis of PNH to pregnancy was 70 months 
(range, 0 to 192), and the mean duration of ecu-
lizumab use before conception was 34 months 
(range, 3 to 115). In 9 women (15%), the diag-
nosis of PNH was made during pregnancy. In 29 
of the 69 pregnancies (42%) that progressed past 
the first trimester, eculizumab therapy was 
started during the second or third trimester. 
One patient in the study discontinued eculizu-
mab therapy at 12 weeks of gestation. All the 
other patients continued therapy with eculizu-
mab throughout the entire postpartum period.
The PNH granulocyte clone size at the time 
eculizumab therapy was initiated was greater 
than 20% in all but one patient who had a granu-
locyte clone size of 4%. In this patient, there was 
Presenting Features Value
At diagnosis
Median age (range) — yr 23 (13–37)
Mean PNH granulocyte clone size (range) 
— %
63.7 (1.6–100)*
Mean hemoglobin level (range) — g/dl 8.5 (4.0–12.7)*
Mean granulocyte count (range) — ×10−9 
per liter
2.38 (0.4–8.9)*
Mean platelet count (range) — ×10−9  
per liter
129 (9–413)*
PNH history — no./total no. (%)
Documented history of aplastic anemia 21/61 (34)
Documented history of thrombotic events 8/61 (13)
Pregnancy before eculizumab treatment
Overall no. 31/31 (100)
Live births 12/31 (39)
Miscarriages 8/31 (26)
Stillbirth 3/31 (10)
Induced abortion 8/31 (26)
Medication at the time of conception  
— no./total no. (%)
Anticoagulation 21/61 (34)
Cyclosporine 4/61 (7)
Eculizumab 32/61 (53)
*  Data on paroxysmal nocturnal hemoglobinuria (PNH) granulocyte clone size, 
hemoglobin level, granulocyte counts, and platelet counts at diagnosis were 
not available for 8, 7, 13, and 6 of the mothers, respectively.
Table 1. Characteristics of the Patients.
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a discrepancy between the granulocyte clone size 
and the monocyte clone size (4% vs. 20%) at the 
start of eculizumab therapy. In addition to anti-
coagulants and eculizumab, other medications 
that were used included aspirin in 4 pregnancies 
(5%), folic acid in 67 pregnancies (89%), and 
iron supplements in 26 pregnancies (35%). Four 
patients were treated with cyclosporine before 
conception and continued to use cyclosporine 
during their pregnancy.
Maternal Complications
Breakthrough intravascular hemolysis, which re-
quired more frequent use or higher doses of ecu-
lizumab or both, was observed in 36 of 67 
pregnancies (54%) that progressed to delivery. 
One patient in whom intravascular hemolysis 
developed was treated with prednisolone for a 
period of 7 days. Transfusion of red cells in-
creased during pregnancy, from a mean of 0.14 
units per month in the 6 months before preg-
nancy to 0.92 units per month during pregnancy. 
Transfusions returned to prepregnancy levels af-
ter delivery. Platelet transfusions were not given 
in any patient before pregnancy, but they were 
given in seven patients during pregnancy and in 
nine additional patients just before and up to 48 
hours after the time of delivery. Hematologic 
status and evolution of hematologic variables dur-
ing and after pregnancy are shown in Figure 1. 
During the postpartum period, two women re-
quired antibiotics for sepsis.
Low-molecular-weight heparin was used in 66 
pregnancies (88%) and fondaparinux in 1 preg-
nancy (1%). Therapeutic doses of low-molecular-
weight heparin were used in 27 pregnancies, 
whereas intermediate doses were used in 7 preg-
nancies and prophylactic doses in 32 pregnan-
cies. Ten bleeding episodes that were considered 
by the clinicians overseeing the patients to be 
clinically significant were documented: 1 episode 
of recurrent epistaxis, 1 of antepartum hemor-
rhage, and 8 of postpartum hemorrhage. Among 
the patients in whom these 10 bleeding episodes 
occurred, one patient had a postpartum hemor-
rhage that required uterine-artery embolization 
and an infusion of a prothrombin complex con-
centrate, and another patient received treatment 
with pooled plasma. Among the patients who 
had bleeding events, two had been receiving 
therapeutic doses of low-molecular-weight hepa-
rin, seven had been receiving prophylactic doses 
of low-molecular-weight heparin, and one had not 
been receiving treatment with an anticoagulant.
No thrombotic events were observed during 
pregnancy. During the postpartum period, a 
thrombotic complication occurred in 2 of the 
75 pregnancies (3%): one involved a deep-vein 
thrombosis in the leg and the other involved a 
mesenteric thrombosis. The mean duration of 
Figure 1. Laboratory Values during and after Pregnancy.
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follow-up after delivery was 19 months (range, 1 to 
72) for all pregnancies.
In addition, 2 other patients who had stopped 
receiving eculizumab 12 weeks after delivery had 
a thrombosis; 1 patient who had continued to 
receive therapeutic doses of low-molecular-weight 
heparin had a mesenteric thrombosis 4 weeks 
after stopping eculizumab therapy, and the other 
patient had Budd–Chiari syndrome 8 weeks after 
stopping eculizumab therapy. Both patients re-
commenced eculizumab therapy — one on the 
day that the thrombosis was radiologically de-
tected and the other a few days after the throm-
bosis was detected — and neither patient had a 
further complication. Overall, eculizumab ther-
apy was discontinued in 10 patients 12 weeks 
after delivery, because there had not been a clini-
cal need for this treatment before pregnancy. 
There were no reports of maternal death in this 
study.
Factors Affecting the Fetus
Six spontaneous abortions occurred during the 
first trimester; in addition, two stillbirths oc-
curred in one patient, at 30 and 32 weeks of 
gestation, and there was one fetal loss at 33 
weeks of gestation in a dichorionic and diam-
niotic twin pregnancy. In the case of all three 
stillbirths, autopsy was declined. In the patient 
who had two stillbirths, a histologic examination 
of the placentas revealed hypotrophy with inter-
villous fibrosis. In the patient who had the twin 
pregnancy, a histologic examination of the pla-
centa confirmed hypotrophy with intervillous fi-
brin and placental abruption. The rate of prema-
ture deliveries (defined as delivery before 37 weeks 
of gestation) was high, at 29% (Table 2). The 
reason for these early deliveries included pre-
eclampsia in six pregnancies, concern over pos-
sible intrauterine growth retardation in five 
pregnancies, falling maternal platelet counts in 
three pregnancies, and reduced fetal movements 
in one pregnancy. The methods of delivery varied, 
with 19 natural deliveries, 16 induced deliveries 
(15 resulted in vaginal deliveries and 1 resulted in 
a cesarean delivery because of failure of progres-
sion to natural labor), and 32 cesarean deliveries.
Characteristics of the Children  
and Complications
Information on birth weight, gestational age, 
neonatal complications, and developmental mile-
stones is shown in Table 3. Neonatal complica-
tions were due mainly to prematurity; six chil-
dren required a prolonged stay in the hospital 
after delivery and one baby had the meconium-
plug syndrome, a functional immaturity of the 
colon associated with prematurity, that required 
a temporary ileostomy. Tests for cystic fibrosis 
in this child were negative.
A total of 25 babies were breast-fed, and in 10 
of these cases, breast milk was examined for the 
presence of eculizumab. The drug was not de-
tected in any of the 10 breast-milk samples. 
Cord-blood samples from 20 deliveries were ex-
amined for the presence of eculizumab; the drug 
was detected in 7 of the 20 samples, with levels 
ranging from 11.8 to 21.2 μg per milliliter.
At the time of this study, the mean age of the 
69 children who survived was 31 months (range, 
4 to 94). Formal developmental assessments 
were available for 64 of the 69 children. There 
were no concerns by the parents with regard to 
childhood development in the 5 children for 
whom information could be obtained only oral-
ly, rather than by formal assessment, and docu-
mented. Only 1 mother and child were lost to 
follow-up. One child was found to have neutro-
penia after delivery, and the condition persisted 
during the first year of life. This child was asymp-
tomatic, and the number of neutrophils returned 
Variable Pregnancies
no. (%)
Fetal complication
Miscarriage during first trimester 6 (8)
Stillbirth 3 (4)
Premature birth 22 (29)
Toxic megacolon 1 (1)
Cause of premature delivery*
Planned cesarean delivery 7 (9)
Preeclampsia 6 (8)
Growth retardation† 5 (7)
Falling platelet count 3 (4)
Reduced fetal movements 1 (1)
*  Premature delivery was defined as delivery before 37 weeks of gestation.
†  Growth retardation was defined as fetal size below the 10th percentile.
Table 2. Fetal Complications and Causes of Premature Delivery  
in 75 Pregnancies.
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to normal by the time the child was 12 months 
of age. One child was referred to a speech and 
language therapist because of slightly delayed 
speech.
Discussion
The introduction of eculizumab for the treat-
ment of patients with PNH has improved the 
management of this illness in that it has reduced 
the mortality and morbidity associated with 
PNH and has allowed patients who were previ-
ously severely affected to lead a relatively normal 
life. PNH tends to manifest in early adulthood, 
and as the symptoms of PNH are reduced with 
the use of eculizumab in young women, it can 
be anticipated that they may consider starting a 
family. Before the use of eculizumab, mortality 
among pregnant women with PNH was unac-
ceptably high (8 to 20%). In the current study, no 
maternal deaths were reported, and only two 
thrombotic events were reported among the pa-
tients who were receiving eculizumab, with both 
events occurring soon after delivery. One of the 
thrombotic events occurred after a plasma infu-
sion was administered to treat a postpartum 
hemorrhage. Plasma contains high levels of com-
plement and can overcome the effects of eculi-
zumab and thereby render the patient suscepti-
ble to complications of PNH. The use of plasma 
should thus be avoided if possible. The other 
thrombotic event was a deep-vein thrombosis in 
a patient’s leg.
Most of the patients (88%) were treated with 
low-molecular-weight heparin from the time of 
confirmation of pregnancy to the end of the 
postpartum period. Because of the low rate of 
maternal thrombosis and maternal mortality, we 
could not determine from the findings in this 
study whether a therapeutic or a prophylactic 
strategy is preferable; however, heparin was a 
part of the routine care in patients with PNH 
during this high-risk period.
Blood products were administered at the dis-
cretion of the treating clinicians. Transfusion of 
red cells increased during the pregnancy but re-
turned to the prepregnancy levels after delivery. 
In a previous study, thrombocytopenia was report-
ed to be a notable issue8; in our study, 16 preg-
nancies (21%) involved platelet transfusions, 
most of which were administered at the time of 
delivery. Granulocyte levels tended to increase 
during the course of the pregnancy; no patient 
had an acute decrease in the number of granulo-
cytes (Fig. 1).
In 36 of 67 pregnancies (54%) that progressed 
to delivery, the dose of eculizumab, the fre-
quency of use of eculizumab, or both were in-
creased for the treatment of symptomatic intra-
vascular hemolysis. Alterations in the dose or 
frequency of use of eculizumab were made at the 
discretion of the treating physician. The dose of 
eculizumab was increased in 23 pregnancies, the 
frequency of use was increased in 9 pregnancies, 
and both the dose and the frequency of use were 
increased in 4 pregnancies. The hemolytic epi-
sodes tended to occur during the third trimester 
— probably related to the increased terminal 
complement activation at this stage of pregnan-
cy.11,12 Eculizumab is metabolized by lysosomal 
enzymes into small peptides and amino acids.25 
The increased activity of lysosomal enzyme acti-
vation, as well as the physiologic changes that 
occur during pregnancy, such as the increase in 
fat and water content, may account for the 
higher doses required.
Three fetal deaths (4%) were documented: 
two stillbirths from the same mother (at 30 and 
Variable Value
Mean birth weight (range) — g 2692 (450–4290)
Mean gestational age (range) — wk 37 (28–41)
Neonatal complication — no./total no.
Prolonged hospital stay 6/69
Initial poor growth 3/69
Meconium-plug syndrome 1/69
Developmental milestone achieved — no./total no.†
Vision 64/64
Hearing 64/64
Locomotion 64/64
Fine-motor skills 64/64
Behavior 64/64
Speech and language 63/64
Physical health 64/64
*  Included are data from the 69 live births among the 75 pregnancies in 61 women.
†  Formal developmental information was not available for 5 of the 69 children. 
The assessments took place at different time points depending on the country 
in which the children were being assessed.
Table 3. Characteristics of Children Born to Women Who Received Eculizumab 
During Pregnancy.*
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32 weeks of gestation) and the loss of a twin in 
another pregnancy. Fetal mortality was similar 
to that in previous reports (4 to 9%) of data ob-
tained before the availability of eculizumab. 
There were six miscarriages during the first tri-
mester, representing a rate of miscarriage of 8%, 
which is lower than the estimated rate of mis-
carriage of 17% among pregnancies in women 
without PNH in the United Kingdom.26 The 
lower rate of miscarriage in our study than that 
in the general population in the United Kingdom 
is probably due to ascertainment bias, because 
29 of the patients did not start eculizumab 
therapy until the second or third trimester.
We found a high rate of premature birth (22 of 
75 pregnancies [29%]), which has been a feature 
in previous reports on pregnancy in women with 
PNH; the corresponding rate among women 
without PNH in the United Kingdom in 2012 
was 7.3%.27 Reasons for premature delivery in-
cluded a planned cesarean delivery (in 2 of the 
twin pregnancies and in 5 other pregnancies), 
preeclampsia, intrauterine growth retardation, 
and falling maternal platelet counts. The high 
rates of hemolysis and premature births high-
light the importance of careful monitoring in 
these patients. Because terminal complement 
activation is elevated in women during the third 
trimester and in women with preeclampsia, ecu-
lizumab may be a useful agent in other high-risk 
situations, such as the HELLP syndrome (which is 
characterized by hemolysis, elevated liver-enzyme 
levels, and low platelet counts), or in the case of 
preeclampsia itself, in which complement dys-
regulation has been reported.28,29
Different methods of delivery were observed 
among the pregnancies that were evaluated, but 
a tendency toward induced labor, to allow the 
delivery to take place in a more controlled man-
ner, was noted in the more recent deliveries. Care 
should be taken after pregnancy if eculizumab 
therapy is to be discontinued, because there may 
be an increased risk of thrombotic complications.
Eculizumab was detected in 7 of 20 cord-
blood samples, which suggests that eculizumab 
may cross the placenta at low levels. In another 
study, two patients with PNH were evaluated at 
delivery, and the mother had no detectable termi-
nal complement activity and both newborns had 
normal complement activity.23 That study sup-
ports the findings of our study that suggest that 
if eculizumab crosses the placenta, the level is not 
high enough to affect complement activation.
A total of 25 babies were breast-fed, and in 
10 of these cases, breast milk was examined for 
the presence of eculizumab; the drug was not 
detected in any of the 10 breast-milk samples. In 
a previous case report, eculizumab was detected 
in the first breast-milk sample in a patient but 
was not detected in subsequent samples, a find-
ing that differs from that in our study.21 We in-
terpret our findings to show that the drug is not 
excreted into breast milk in measurable amounts 
and that breast-feeding by patients receiving ecu-
lizumab is safe.
A comparison of maternal and fetal mortality 
among the pregnancies in our study with mater-
nal and fetal mortality among pregnancies that 
were described before eculizumab was available 
is difficult and is subject to potential selection 
bias because the patients were studied retrospec-
tively. However, it is not feasible to conduct a study 
comparing patients with PNH who receive eculi-
zumab during pregnancy with those who do not 
receive eculizumab during pregnancy, partly be-
cause of the rarity of the condition but also be-
cause pregnancy has been discouraged in women 
who are not receiving eculizumab. A contempo-
rary randomized study would not be ethical.
Overall, our findings showed acceptable out-
comes when eculizumab treatment was used in 
the management of PNH in patients during preg-
nancy. Both hematologists and obstetrical care 
specialists participated in the delivered care to 
achieve the outcomes reported.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
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